Eagle Wealth Strategies’s Akebia Therapeutics AKBA Stock Holding History

Eagle Wealth Strategies’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.4K	Hold	10,000	–	–	﹤0.01%	118
2026 Q1	$13.9K	Hold	10,000	–	–	0.01%	112
2025 Q4	$16.1K	Hold	10,000	–	–	0.01%	113
2025 Q3	$27.3K	Hold	10,000	–	–	0.01%	106
2025 Q2	$36.4K	Hold	10,000	–	–	0.02%	103
2025 Q1	$19.2K	Hold	10,000	–	–	0.01%	97
2024 Q4	$19K	Hold	10,000	–	–	0.01%	105
2024 Q3	$13.2K	Sell	10,000 -2,000	-17%	-$2.67K	0.01%	109
2024 Q2	$12.2K	Hold	12,000	–	–	0.01%	89
2024 Q1	$19.6K	Sell	12,000 -8,017	-40%	-$12.8K	0.02%	94
2023 Q4	$24.8K	Buy	+20,017	New	+$20.4K	0.02%	98

Other funds holding AKBA

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

IWN

Independent Wealth Network Urbandale, Iowa $393M AUM 30.08% 1-Year Est. Return

LPT

Legacy Private Trust Neenah, Wisconsin $1.81B AUM 19.87% 1-Year Est. Return

JWCA

J.W. Cole Advisors Tampa, Florida $5.83B AUM 32.38% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Eagle Wealth Strategies's AKBA Position: Q2 2026 in Review

Eagle Wealth Strategies held its Akebia Therapeutics (AKBA) position steady in Q2 2026 at 10,000 shares worth $11.4K. The position accounts for ﹤0.01% of the portfolio, ranked #118.

Eagle Wealth Strategies first reported a position in AKBA in Q4 2023 and has held it in 11 quarters since. The position peaked at $36.4K in Q2 2025. 15 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

Eagle Wealth Strategies held 10,000 shares of Akebia Therapeutics worth $11.4K as of Q2 2026.
Eagle Wealth Strategies left its Akebia Therapeutics share count unchanged in Q2 2026.
Akebia Therapeutics made up ﹤0.01% of Eagle Wealth Strategies's portfolio in Q2 2026, its #118 holding.
Eagle Wealth Strategies first reported a position in Akebia Therapeutics in Q4 2023 and has held it in 11 quarters since.
Eagle Wealth Strategies's Akebia Therapeutics position peaked at $36.4K in Q2 2025.
15 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Eagle Wealth Strategies's 13F filing for Q2 2026, filed 9 Jul 2026.